🇺🇸 FDA
Pipeline program

ADX-102 Ophthalmic Solution (0.5%)

ADX-102-UV-005

Phase 3 small_molecule completed

Quick answer

ADX-102 Ophthalmic Solution (0.5%) for Non-infectious Anterior Uveitis is a Phase 3 program (small_molecule) at Aldeyra Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aldeyra Therapeutics
Indication
Non-infectious Anterior Uveitis
Phase
Phase 3
Modality
small_molecule
Status
completed

Clinical trials